MedPath
HSA Approval

CYTARINE KABI SOLUTION FOR INJECTION OR INFUSION 100MG/ML

SIN17149P

CYTARINE KABI SOLUTION FOR INJECTION OR INFUSION 100MG/ML

CYTARINE KABI SOLUTION FOR INJECTION OR INFUSION 100MG/ML

December 18, 2024

FRESENIUS KABI (SINGAPORE) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantFRESENIUS KABI (SINGAPORE) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, SOLUTION

INTRAVENOUS, SUBCUTANEOUS

Medical Information

L01BC01

Manufacturer Information

FRESENIUS KABI (SINGAPORE) PTE LTD

Fresenius Kabi Oncology Ltd.

Active Ingredients

Cytarabine

100 mg/ml

Cytarabine

Documents

Package Inserts

Cytarine Kabi Solution for Injection or Infusion PI.pdf

Approved: December 18, 2024

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

CYTARINE KABI SOLUTION FOR INJECTION OR INFUSION 100MG/ML - HSA Approval | MedPath